Skip to content

Coeptis Therapeutics Inc.

company.status.inactive

CIK 1819663fmd_1BN0WNMHX6EPG3Y35G8XA573BNManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Dec 01, 2018 to Sep 30, 2022, 15 periods

Latest annual · FY2021

Millions
Total revenues
0
Gross profit
0
Operating income
(14)
Net income
(13)
Free cash flow
(4)

Latest quarter · Q3 FY2022

Millions
Total revenues
0
Gross profit
0
Operating income
(6)
Net income
(6)
Open Financials

Coeptis Therapeutics Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2021FY2020ChangeSource
Revenue$75,000$30,761+143.8%10-K 2022-03-11 · proof
Gross profit$75,000-$933,45610-K 2022-03-11 · proof
Operating income-$14.2 million-$6.9 million10-K 2022-03-11 · proof
Net income-$13.4 million-$9.2 million10-K 2022-03-11 · proof
Cash from operating activities-$4.5 million-$3.1 million10-K 2022-03-11 · proof
Free cash flow-$4.5 million-$3.1 million10-K 2022-03-11 · proof
Total assets$6.8 million$300,484+2,151.6%10-K 2022-03-11 · proof
Total liabilities$4.4 million$5.4 million-18.9%10-K 2022-03-11 · proof
Cash and cash equivalents$2.2 million$202,965+973.9%10-K 2022-03-11 · proof
What was Coeptis Therapeutics Inc.'s revenue in fiscal 2021?
Coeptis Therapeutics Inc. reported revenue of $75,000 for fiscal 2021 (the year ended Dec 31, 2021), against $30,761 the year before (+143.8%). Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What was Coeptis Therapeutics Inc.'s gross profit in fiscal 2021?
Coeptis Therapeutics Inc. reported gross profit of $75,000 for fiscal 2021 (the year ended Dec 31, 2021), against -$933,456 the year before. Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What was Coeptis Therapeutics Inc.'s operating income in fiscal 2021?
Coeptis Therapeutics Inc. reported operating income of -$14.2 million for fiscal 2021 (the year ended Dec 31, 2021), against -$6.9 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What was Coeptis Therapeutics Inc.'s net income in fiscal 2021?
Coeptis Therapeutics Inc. reported net income of -$13.4 million for fiscal 2021 (the year ended Dec 31, 2021), against -$9.2 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What was Coeptis Therapeutics Inc.'s cash from operating activities in fiscal 2021?
Coeptis Therapeutics Inc. reported cash from operating activities of -$4.5 million for fiscal 2021 (the year ended Dec 31, 2021), against -$3.1 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What was Coeptis Therapeutics Inc.'s free cash flow in fiscal 2021?
Coeptis Therapeutics Inc. reported free cash flow of -$4.5 million for fiscal 2021 (the year ended Dec 31, 2021), against -$3.1 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What are Coeptis Therapeutics Inc.'s total assets?
As of Dec 31, 2021, Coeptis Therapeutics Inc. reported total assets of $6.8 million, against $300,484 a year earlier (+2,151.6%). Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What are Coeptis Therapeutics Inc.'s total liabilities?
As of Dec 31, 2021, Coeptis Therapeutics Inc. reported total liabilities of $4.4 million, against $5.4 million a year earlier (-18.9%). Source: the 10-K filed with the SEC on Mar 11, 2022. SEC
What are Coeptis Therapeutics Inc.'s cash and cash equivalents?
As of Dec 31, 2021, Coeptis Therapeutics Inc. reported cash and cash equivalents of $2.2 million, against $202,965 a year earlier (+973.9%). Source: the 10-K filed with the SEC on Mar 11, 2022. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1819663&period_type=annual&limit=5"

Information only, not investment advice.